Article Text

Download PDFPDF

Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis
  1. Tadashi Senoo1,
  2. Noboru Hattori1,
  3. Takuya Tanimoto1,
  4. Makoto Furonaka1,
  5. Nobuhisa Ishikawa1,
  6. Kazunori Fujitaka1,
  7. Yoshinori Haruta1,
  8. Hiroshi Murai1,
  9. Akihito Yokoyama2,
  10. Nobuoki Kohno1
  1. 1Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
  2. 2Department of Hematology and Respiratory Medicine, Kochi University, Kochi, Japan
  1. Correspondence to Dr Noboru Hattori, Department of Molecular and Internal Medicine, Graduate School of Biomedical, Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan; nhattori{at}hiroshima-u.ac.jp

Abstract

Background and aim There is a growing body of evidence demonstrating that plasminogen activator inhibitor-1 (PAI-1) is involved in the progression of pulmonary fibrosis. In fact, PAI-1 knockout mice are protected from bleomycin-induced pulmonary fibrosis. This study was conducted to determine whether the intrapulmonary administration of small interfering RNA (siRNA) targeting PAI-1 (PAI-1-siRNA) limits the development of bleomycin-induced pulmonary fibrosis.

Methods Lung biopsies from patients with idiopathic pulmonary fibrosis (IPF) were stained for PAI-1. The distribution of siRNA in the lung, the PAI-1 level in bronchoalveolar (BAL) fluid and the extent of fibrotic changes in the lung were evaluated following the intranasal administration of PAI-1-siRNA in a mouse model of bleomycin-induced pulmonary fibrosis. The effect of PAI-1-siRNA on the epithelial to mesenchymal transition (EMT) was also evaluated using a mouse lung epithelial cell line, LA-4.

Results PAI-1 was overexpressed in the hyperplastic type 2 pneumocytes lining the honeycomb lesions of patients with IPF. The single intranasal instillation of PAI-1-siRNA resulted in the diffuse uptake of siRNA into the epithelial cells lining the dense fibrotic lesions. The repeated administration of PAI-1-siRNA initiated during either the inflammatory or the fibrotic phase into bleomycin-injured mice reduced the PAI-1 level in BAL fluid and limited the accumulation of collagen in the lungs. EMT induced by transforming growth factor β (TGFβ) in LA-4 cells was inhibited by transfection with PAI-1-siRNA.

Conclusions The direct suppression of PAI-1 in the lung by the intrapulmonary administration of PAI-1-siRNA attenuated the development and progression of pulmonary fibrosis. The inhibition of EMT may be, at least in part, involved in this effect.

  • Bleomycin
  • epithelial to mesenchymal transition (EMT)
  • interstitial fibrosis
  • plasminogen activator inhibitors
  • small interfering RNA
View Full Text

Statistics from Altmetric.com

Supplementary materials

Footnotes

  • Funding This work was supported by a grant to the Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare, Japan, and a grant from Okamoto Satoshi Memorial Fund for Pulmonary Fibrosis Research.

  • Competing interest None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.